

BÖLÜM

1

# KARACİĞER HASTALIKLARI

*Sefa TÜRKOĞLU<sup>1</sup>*

**Vaka 1:** Kavernöz Hemanjiyom

**Vaka 2:** Fokal Nodüler Hiperplazi (FNH)

**Vaka 3:** Fokal Yağlanması

**Vaka 4:** Karaciğerde Demir Birikimi

**Vaka 5:** Hepatosellüler Karsinom (HCC)

**Vaka 6:** Kolanjiyosellüler Karsinom

**Vaka 7:** Kolon Kanseri Kalsifik Karaciğer Metastazları

---

<sup>1</sup> Uzman Doktor, Denizli Devlet Hastanesi Radyoloji Kliniği, radyologst@gmail.com

manjiyom, fibrolameller HCC ve kolanjiyokarsinom sayılabilir. Meme kanseri metastazı nedeniyle kemoterapi alan hastalarda karaciğerde siroz benzeri bulgular gelişebilir (43).

## Önemli Noktalar

---

Metastazlar karaciğerin en sık malign lezyonları olup, primer malign karaciğer tümörlerinden daha sık izlenirler (44). USG'de spesifik bulgusu yoktur. Hipo, izo ya da hiperekoik olabilirler. İzoekoik lezyon çevresindeki hipoekoik halo metastazın tipik USG görüntüsüdür. Meme kanseri metastazları diffüz tutulum yapabilir ve bu durum USG'de ayırt edilemeyebilir. BT ve MRG'de kontrast tutulumuna göre metastazlar hipo ya da hipervasküler olarak izlenirler. Nöroendokrin tümör, RCC, tiroid karsinomu, melanoma ve sarkom metastazları hipervasküler metastazlara örnek olarak verilebilir. Bunların dışındaki kanserlerin metastazları genellikle hipovaskülerdir (18).

## Tuzaklar

---

Tedavi edilen metastazlar hemanjiyom benzeri erken periferik kontrastlanma ve geç kontrast tutulumu gösterebileceği akılda tutulmalıdır (42).

## Tedavi ve Yaklaşım

---

Cerrahi, medikal tedavi, transarteriyel kemoembolizasyon ve radyofrekans ablasyon uygulanabilecek tedavi yöntemleridir.

## KAYNAKLAR

---

- Caseiro-Alves F, Brito J, Araujo AE, et al. Liver haemangioma: common and uncommon findings and how to improve the differential diagnosis. *Eur Radiol*. 2007;17(6):1544-54. Epub 2007 Jan 27. Doi:10.1007/s00330-006-0503-z.
- Klotz T, Montoriol PF, Da Ines D, et al. Hepatic haemangioma: common and uncommon imaging features. *Diagn Interv Imaging*. 2013;94(9):849-859. Doi: 10.1016/j.diii.2013.04.008. Epub 2013 Jun 21.
- Vilgrain V, Boulous L, Vullierme MP, et al. Imaging of atypical hemangiomas of the liver with pathologic correlation. *Radiographics*. 2000;20(2):379-397. Doi:10.1148/radiographics.20.2.g00mc01379.
- Kim KW, Kim MJ, Lee SS, et al. Sparing of fatty infiltration around focal hepatic lesions in patients with hepatic steatosis: sonographic appearance with CT and MRI correlation. *AJR Am J Roentgenol* 2008;190(4):1018—1027. Doi:10.2214/AJR.07.2863.
- Bajenaru N, Balaban V, Savulescu F, et al. Hepatic hemangioma -review-. *Journal of Medicine and Life* Vol. 8, Special Issue, 2015, pp.4-11.
- Schwartz SI, Husser WC. Cavernous hemangioma of the liver. A single institution report of 16 resections. *Ann Surg*. 1987;205(5):456-465. DOI:10.1097/00000658-198705000-00003.
- Ronot M, Vilgrain V. Imaging of benign hepatocellular lesions: Current concepts and recent updates. *Clin Res Hepatol Gastroenterol*. 2014 Dec;38(6):681-8. Doi: 10.1016/j.clinre.2014.01.014. Epub 2014 Mar 11.
- Ros PR, Menu Y, Vilgrain V, et al. Liver neoplasms and tumor-like conditions. *Eur Radiol* 2001; 11(Suppl 2):S145-S165.

9. Ishak KG, Goodman ZD, Stocker JT (2001) Tumors of the liver and intrahepatic bile ducts. Washington, DC: Armed Forces Institute of Pathology.
10. Kondo F, Nagao T, Sato T, et al. (1998) Etiological analysis of focal nodular hyperplasia of the liver, with emphasis on similar abnormal vasculatures to nodular regenerative hyperplasia and idiopathic portal hypertension. *Pathol Res Pract* 1988; 194:487–495. Doi:10.1016/S0344-0338(98)80117-9.
11. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. *Hepatology*. 1985;5:1194–1200. Doi:10.1002/hep.1840050622.
12. Agarwal S, Fuentes-Orrego J.M, Arnason T, et al. Inflammatory Hepatocellular Adenomas Can Mimic Focal Nodular Hyperplasia on Gadoxetic Acid-Enhanced MRI. *American Journal of Roentgenology*. 2014;203: 408-414. 10.2214/AJR.13.12251. Doi:10.2214/AJR.13.12251.
13. Ott R, Hohenberger W. Focal nodular hyperplasia and liver cell adenoma: operation or observation? *Zentralbl Chir* 1998;123:145-153.
14. Kroncke TJ, Taupitz M, Kivelitz D, et al. Multifocal nodular fatty infiltration of the liver mimicking metastatic disease on CT: imaging findings and diagnosis using MR imaging. *Eur Radiol*. 2000;10:1095-1100. Doi:10.1007/s003300000360.
15. Karcaaltincaba M, Akhan O. Imaging of hepatic steatosis and fatty sparing. *Eur J Radiol*. 2007;61:33-43. Doi:10.1016/j.ejrad.2006.11.005.
16. Hamer OW, Aguirre DA, Casola G, et al. Fatty liver: imaging patterns and pitfalls. *Radiographics*. 2006;26:1637-1653. <https://doi.org/10.1148/rg.266065004>.
17. Prasad SR, Wang H, Rosas H, et al. Fat-containing lesions of the liver: radiologic-pathologic correlation. *Radiographics*. 2005;25:321-331. Doi:10.1148/rg.252045083.
18. Karaosmanoğlu AD, Ünal E, Karçaaltınçaba M. (2014). Karaciğer (Ercan Kocakoç E.d.), *Abdominal Radyoloji içinde* (s 169-219). Ankara: Dünya Tip Kitapları.
19. Andrews NC. Disorders of iron metabolism. *N Engl J Med* 1999;341:1986–1995. Doi:10.1056/NEJM199912233412607.
20. Guyader D, Gandon Y, Deugnier Y, et al. Evaluation of computed tomography in the assessment of liver iron overload: a study of 46 cases of idiopathic hemochromatosis. *Gastroenterology* 1989;97:737–743. Doi:10.1016/0016-5085(89)90646-x.
21. Howard JM, Ghent CN, Carey LS, et al. Diagnostic efficacy of hepatic computed tomography in the detection of body iron overload. *Gastroenterology* 1983;84:209–215.
22. van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. *Eur J Cancer* 2011;47(12):1789–1797.
23. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. *Best Pract Res Clin Gastroenterol* 2005;19(1):3–23.
24. El-Serag HB. Hepatocellular carcinoma. *N Engl J Med* 2011;365(12):1118–1127.
25. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. *J Hepatol* 2012;56(6):1384–1391.
26. Lencioni R, Cioni D, Bartolozzi C. Hepatocellular carcinoma. In: Terrier F, Grossholz M, Becker CD, ed. *Spiral CT of the abdomen*. 2nd ed. Berlin: Springer, 2002; 111-132.
27. Kim MJ, Choi JY, Lim JS, et al. Optimalscan window for detection of hypervasculär hepatocellular carcinomas during MDCT examination. *AJR Am J Roentgenol* 2006;187(1):198–206.
28. Murakami T, Hori M, Kim T, Kawata S, Abe H, Nakamura H. Multidetector row CT and MR imaging in diagnosing hepatocellular carcinoma. *Intervirology* 2004;47(3-5):209–226.
29. Obuz F. Hepatosellüler Karsinomda Radyolojik Tanı ve Evreleme. Türk Radyoloji Seminerleri, Trd Sem 2015; 3: 437-60.
30. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. *Curr Opin Gastroenterol* 2007; 23:317–323.
31. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. *Semin Liver Dis* 2004;24:115–125.
32. Khan SA, Davidson BR, Goldin R, et al. British Society of Gastroenterology: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. *Gut*. 2002;51(suppl6):VI1–9.
33. Khan SA, Thomas HC, Davidson BR, et. Al. Cholangiocarcinoma. *Lancet* 2005;366:1303–1314.
34. Ghouri YA, Mian I, Blechacz B. Cancer review: Cholangiocarcinoma. *J Carcinog* 2015;14: 1.
35. Neitlich JD, Topazian M, Smith RC, et al. Detection of choledocholithiasis: comparison of unenhanced helical CT and endoscopic retrograde cholangiopancreatography. *Radiology* 1997;203:753–757.
36. Jung AY, Lee JM, Choi SH, et al: CT features of an intraductal polypoid mass: differentiation between hepatocellular carcinoma with bile duct tumor invasion and intraductal papillary cholangiocarcinoma. *J Comput Assisi Tomogr* 2006;30:173–181.
37. Chung YE, Kim MJ, Park YN, et al: Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. *Radiographics* 2009;29:683–700.

38. Ayuso JR, Pages M, Darnell A: Imaging bile duct tumors: staging. *Abdom Imaging* 2013;38:1071–1081.
39. Zhang GQ, Zhang ZW, Lau WY, Chen XP: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a new strategy to increase resectability in liver surgery. *Int J Surg* 2014;12:437–441.
40. Zhou L, Cui MY, Xiong J, et al. Spectrum of appearances on CT and MRI of hepatic epithelioid hemangioendothelioma. *BMC Gastroenterol* 2015; 15: 69.
41. Fowler KJ, Brown JJ, Narra VR. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. *Hepatology*. 2011;54:2227-37.
42. Coenegrachts K. Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions. *World J Radiol* 2009;1:72-85.
43. Gürcan N.I. Karaciğerin HCC Dışındaki Malign Tümörleri. Türk Radyoloji Seminerleri, Trd Sem. 2015;3:423-436.
44. Gore RM, Thakrar KH, Wenzke DR, et al. That liver lesion on MDCT in the oncology patient: is it important? *Cancer Imaging*. 2012;12:373-384.